<unk>  is a CD20-directed cytolytic monoclonal antibody that is FDA approved for the treatment of previously untreated patients with chronic lymphocytic leukemia (CLL) in combination with chlorambucil and patients with CLL refractory to fludarabine and alemtuzumab. There is a Black Box Warning for this drug as shown here.  Common adverse reactions include infusion reactions, neutropenia, pneumonia, pyrexia, cough, diarrhea, anemia, fatigue, dyspnea, rash, nausea, bronchitis, and upper respiratory tract infections.
Ofatumumab
Adecatumumab
Lexatumumab
Daratumumab
Alirocumab
Raxibacumab
Lanadelumab
Acalabrutinib